
Item ID Number 01865

Author Greenwald, Peter

Corporate Author State of New York Department of Health, Office of Public Health

Report/Article Title Epidemiological Study of Soft-Tissue Sarcoma

Journal/Book Title

Year 1981

Month/Day January

Color

Number of Images 28

Description Notes project period: February 1, 1981 - March 31, 1983.
Item includes 1) State of New York Senate Assembly
May 6, 1980 establishing a temporary state commission
on dioxin exposure, etc. 2) Sample New York State
Department of Health Certificate of Death

STATE OF NEW YORK
DEPARTMENT OF HEALTH  OFFICE OF PUBLIC HEALTH

TOWER BUILDING • THE GOVERNOR NELSON A. ROCKEFELLER EMPIRE STATE PLAZA • ALBANY, N.Y. 12237

DAVID AXELROD, M.D.

Commissioner

GLENN E. HAUGHIE, M.D.

Director of Public Health

DIVISION OF EPIDEMIOLOGY

PETER GREENWALD, M.D., DR. P.H.

Director

Epidemiological Study of Soft-Tissue Sarcoma

Peter Greenwald, M.D., Director, Division of Epidemiology
N.Y.S. Department of Health, NARESP - Tower Bldg. - Rm. 503,
Albany, New York 12237, (518) 474-2353

Project Period: February 1, 1981 - March 31, 1983

Performance Site: New York State, Exclusive of New York City

January 1981

Abstract

Military experience of men in upstate New York reported with soft-tissue sarcomas will be studied epidemiologically for Vietnam service with potential herbicide exposure. Case ascertainment will be via the New York State Cancer Registry of men 18 through 29 years of age at any time from 1962 through 1971 and followed through December 31, 1980. Age and area-matched control groups will be selected from death certificates and drivers license files. Military service experience will be obtained from notations on death certificates, hospital records, telephone interviews, and Veterans Administration or Department of Defense records. Other factors previously suspected as being associated with soft-tissue sarcoma also will be studied.

In addition, occupation and industry of all men age 20 and over dying with soft-tissue sarcomas as residents of upstate New York from January 1, 1970 through December 31, 1980 will be examined. Matched controls will be selected from death certificates. The purpose of this study is to determine whether any occupation or industry is over-represented among the case group, thus raising a question of whether occupational or industrial exposure in New York State may contribute to soft-tissue sarcoma.

Specific Aims

- 1) To determine if men in New York State exclusive of New York City of draftable ages during the Vietnam War and reported to the New York State Cancer Registry as having soft-tissue sarcoma through December 31, 1980 were more likely to serve in Vietnam than an age-matched control group.
- 2) To compare areas of service within Vietnam by case and control veterans who served in Vietnam, in order to attempt to assess potential for herbicide exposure.
- 3) To compare the histopathology and anatomic site of soft-tissue sarcomas amongst Vietnam veterans to the site and pathology of sarcomas in non-Vietnam veterans and non-veterans.
- 4) To determine whether deaths from soft-tissue sarcoma are associated with occupations or industries in New York State, as identified through death certificate reports.

Legislative Mandate

The New York State Legislature determined that there is a public need to know the health effects of exposure to herbicides containing dioxin for residents of the State of New York, including those Vietnam era veterans who may have been exposed to these substances during their period of military service. The New York State Public Health Law was amended effective September 1, 1980 to require the Commissioner of Health to "initiate an Epidemiological Study of the health effects of exposure to herbicides containing Dioxin." This project is developed as part of the response to this new legislation.

Preliminary Studies

In a report from Sweden, Hardell and Sandstrom (1979) reported a six-fold increase in the risk for soft-tissue sarcomas in workers exposed in phenoxyacetic acids or chlorophenols. Phenoxy herbicides have been used to control unwanted hardwoods in Swedish forests and commercial preparations nearly always are contaminated with dioxin. The Hardell and Sandstrom study explored potential for exposure among 52 men with soft-tissue sarcoma and reported that 19 of the 52 men may have had exposure compared to 19 of 208 control men. Soft-tissue sarcomas are a broad category of tumors derived from different types of cells and the authors did not provide information about which specific histologic types were studied. Nevertheless, a striking conclusion necessitates independent study of this reported association.

The New York State Cancer Registry was searched for soft-tissue sarcomas among men born between January 1, 1933 and December 31, 1953 who had attained the age of 18 years or more. This cohort includes men 18-29 during the years 1962-71.

The sites of cancer selected and International Classification of Disease codes (9th revision) are as follows:

- Connective and Other Soft Tissues (171)
 - Head, Face and Neck (171.0)
 - Upper Limb, including Shoulder (171.2)
 - Lower Limb, including Hip (171.3)
 - Thorax (171.4)
 - Abdomen (171.5)
 - Pelvis (171.6)
 - Trunk, Unspecified (171.7)
 - Other (171.8)
 - Site Unspecified (171.9)

In addition, malignant neoplasms of the retroperitoneum and peritoneum (158) as well as those of the thymus, heart and mediastinum (164) will be reviewed in order to locate all possible soft tissue tumors.

The number of men in the Vietnam era cohort reported to the Registry, classified according to the American Cancer Society's 1968 Manual of Tumor Nomenclature and Coding (MONTAC), are as follows:

ICD 171 Connective and Other Soft Tissues		Total = 250
800	Neoplasm, Malignant	18
807	Squamous Cell Carcinoma, NOS	1
869	Nonchromaffin Paraganglioma, Malignant	1
880	Sarcoma, NOS	12
881	Fascial Fibrosarcoma	2
882	Fibrosarcoma, NOS	42
883	Fibroanthoma, Malignant	13
884	Myxosarcoma	1
885	Liposarcoma	41
889	Leiomyosarcoma	17
890	Rhabdomyosarcoma, NOS	11
891	Embryonal Rhabdomyosarcoma	4
892	Alveolar Rhabdomyosarcoma	1
899	Mesenchymoma, Malignant	6
904	Synovial Sarcoma	28
905	Mesothelioma, Malignant	1
912	Hemangiosarcoma	4
913	Hemangioendothelioma, Malignant	2
914	Kaposi's Sarcoma	4
915	Hemangiopericytoma, Malignant	6
922	Chondrosarcoma	1
937	Granular Cell Myoblastoma, Malignant	6
939	Ependymoma, Malignant	1
949	Ganglioneuroblastoma	1
950	Neuroblastoma, NOS	2
954	Neurofibrosarcoma	9
956	Neurilemoma, Malignant	15

The following tables show the distribution of these tumors by anatomic site and by geographic area within New York State:

Table 1

Connective and Other Soft-Tissue Tumors
Among Men in Vietnam Era Cohort

New York State Cancer Registry
Anatomic Site

171	Connective and Other Soft Tissues	Total = 250
171.0	Head, Face and Neck	19
171.2	Upper Limb, Including Shoulder	26
171.3	Lower Limb, Including Hip	101
171.4	Thorax	2
171.5	Abdomen	2
171.6	Pelvis	6
171.7	Trunk, Unspecified	33
171.8	Other	-
171.9	Site Unspecified	61

Table 2

Connective and Other Soft-Tissue Tumors
Among Men in Vietnam Era Cohort
 New York State Cancer Registry
Histologic Type by Anatomic Site

Anatomic Site & Histologic Type	Head, Face and Neck (171.0)	Upper Limb, Including Shoulder (171.2)	Lower Limb, Including Hip (171.3)	Thorax (171.4)	Abdomen (171.5)	Pelvis (171.6)	Trunk, Unspecified (171.7)	Other (171.8)	Site Unspecified
800 Neoplasm, Malignant	1						2		15
807 Squamous Cell Carcinoma, NOS	1								
869 Nonchromaffin Paraganglioma, Malignant	1								
880 Sarcoma, NOS			8				2		2
881 Fascial Fibrosarcoma	2								
882 Fibrosarcoma, NOS	4	7	14		1	2	8		6
883 Fibroxanthoma, Malignant	4	2	4				1		2
884 Myxosarcoma			1						
885 Liposarcoma	3	1	28	1	1	2	2		3
889 Leiomyosarcoma		4	6				3		4
890 Rhabdomyosarcoma, NOS			8				1		2
891 Embryonal Rhabdomyosarcoma		1	1			1	1		
892 Alveolar Rhabdomyosarcoma			1						
899 Mesenchymoma, Malignant	1		1				4		
904 Synovial Sarcoma		5	16				5		2
905 Mesothelioma, Malignant							1		
912 Hemangiosarcoma		1	1				1		1
913 Hemangioendothelioma, Malignant		1	1						
914 Kaposi's Sarcoma		2	2						
915 Hemangiopericytoma, Malignant		2	1				1		2
922 Chondrosarcoma	1								
937 Granular Cell Myoblastoma, Malignant			4						2
939 Ependymoma, Malignant									1
949 Ganglioneuroblastoma									1
950 Neuroblastoma, NOS									2
954 Neurofibrosarcoma			1	1			1		6
956 Neuroilemoma, Malignant	1		3			1			10
All Histologic Types	19	26	101	2	2	6	33	-	61

Table 3Connective and Other Soft-Tissue Tumors
Among Men in Vietnam Era CohortNew York State Cancer Registry
Geographic Distribution

New York State, exclusive of New York City	Total = 250
Buffalo Region	37
Rochester Region	27
Syracuse Region	37
Binghamton Region	8
Albany Region	45
Westchester Region	49
Long Island	45
Unknown Residence	2

Epidemiological reports on soft-tissue sarcomas are scant. Several factors have been hypothesized to be important to etiology but little evidence has been provided in support of these ideas. The main factors are as follows:

- 1) Trauma. Fibrosarcomas occasionally develop in scar tissue (Stout, 1961). It is doubtful that sarcomas develop from contusing blows although this has not been ruled out. Local sarcoma of the rat may be induced by the subcutaneous injection of many substances. In particular implants of a variety of plastic or metal discs or films can induce sarcomas in rats and mice. The relevance of this to man is uncertain (Lancet editorial, 1969). Greenberg (1976) reported four cases of sarcoma of the buttocks following intramuscular iron injection.

Morman, et al (1979) reported a locally aggressive dermatofibrosarcoma in a soldier who had received multiple immunizations for plague, yellow fever and tetanus. The sarcoma developed at the injection site. Five months after the injection a small nodule was noted, and eight years later gradual enlargement was first observed.

- 2) Infection. Morton (1974, 1969) outlined the observations which suggest the close association of a viral agent with human sarcomas. Morton writes:

- "1. Type C viral particles, morphologically similar to the avian, murine, and feline sarcoma viruses, have been seen in human sarcomas.
- "2. All different types of human skeletal and soft-tissue sarcomas contain a common sarcoma-specific antigen to which patients with these neoplasms form antibody. Since all animal neoplasms induced by the same virus contain a common virus-specific tumor antigen, the finding of a common antigen in human sarcomas suggests viral etiology of these neoplasms by analogy.
- "3. Relatives and close associates of sarcoma patients also possess a high incidence of antibody to the sarcoma-specific antigens...."

Kaposi's sarcoma has been reported in association with lymphoreticular malignancies (Safai, et al, 1980). These investigators note clustering of Kaposi's sarcoma in endemic areas and cytomegalovirus isolation from a Kaposi's sarcoma culture cell line. A mechanism is hypothesized by which cytomegalovirus can lead to the development of multiple primary malignancies in Kaposi's sarcoma patients.

Soft-tissue sarcomas are said to be common in Afghanistan, ranking third among cancers (Sobin, 1968). Sobin believes that sarcomas could be related to arthropod vectors. He contends that subepidermal connective tissue is particularly exposed to mosquitos and other arthropods which pierce the

epidermis. The hamster reticulum cell sarcoma has been transmitted by a mosquito by transfer of tumor cells and the Shope fibroma virus can be transmitted by bites of fleas and mosquitos. Sobin further speculates that the distribution of bites from crawling arthropods, for example, fleas, ticks and bedbugs, may relate to the common location of soft-tissue sarcoma on lower extremities, and finally, he believes that the age incidence is compatible with an arthropod vector. Unfortunately, little data are provided to support these contentions.

No difference in family exposure to domestic cats, dogs and parakeets was found by Hanes, et al (1970) in a survey of households which included 127 persons with sarcoma.

- 3) Radiation. Eleven patients with postirradiation sarcoma have been described by Hatfield and Schulz (1970). These followed radiation treatment of primary carcinoma of the breast, three after megavoltage therapy. Other reports also indicate that radiation may induce sarcomas.
- 4) Familial Occurrence. Li and Fraumeni (1969, 1969, 1975) reported several families with more than one member having rhabdomyosarcoma and other soft-tissue sarcomas or other cancers. Mierau and Favara (1980) felt that all childhood forms of rhabdomyosarcoma are essentially embryonal tumors based on ultrastructural

study. In one series four of twenty children with soft-tissue sarcomas had associated congenital anomalies (Sloane and Hubbell, 1969). The simultaneous occurrence of sarcomas in a husband and wife was reported by Goldenberg, et al (1974).

- 5) Chemicals. The possible association with dioxins raises questions about the induction of sarcomas by other chemicals. As noted above, intramuscular iron and multiple immunizations have been suspect. In this study, the main effort to obtain a lead on other potential chemicals will focus on occupation and industry.

Methods

I. Cancer Study

(a) Case Ascertainment - The case group will be all male residents of New York State exclusive of New York City who were 18 to 29 years old anytime from 1962 - 1971, and who were reported to the New York State Cancer Registry as having soft-tissue sarcoma first diagnosed at any time through December 31, 1980.

The New York State Department of Health maintains one of the world's largest cancer registries. By law all physicians, hospitals, and laboratories must report newly diagnosed patients with cancer to the New York State Cancer Registry. We believe this Registry to be about 90% complete. A copy of the cancer registry report form is shown below.

New York State Cancer Registry Report

MALIGNANT NEOPLASM - CONFIDENTIAL CASE REPORT										Date of the Report		District No.					
NAME OF PATIENT (Please Print)					Last Name					First	Initial	Major Name					
PERMANENT ADDRESS										AGE		DATE OF BIRTH					
Street												Month		Day		Year	
City																	
Town																	
Village																	
ZIP Code										Country		SEX		M		F	
COLOR RACE	White	Black	Indian	Chinese	Japanese	P.R. Incl. Pac.	Other	O. Span. Orig.	Una.	MARITAL STATUS		S	M	Wid.	Div.	Sep.	Una.
SOCIAL SECURITY NUMBER	DATE OF DIAGNOSIS				Month		Year		STATE OR COUNTRY OF BIRTH								
PRIMARY SITE										HISTOLOGIC TYPE		MICROSCOPICALLY CONFIRMED					
												Yes		No		Una.	
IS THIS THE FIRST PRIMARY MALIGNANT NEOPLASM?										Yes	No	Una.	STAGE OF DISEASE WHEN FIRST DIAGNOSED BY PHYSICIAN REPORTING				
													In Situ	Local	Reg. Ext.	Metastatic	Unknown
CIGARETTE ?	Present	Former	Never	Una.	NAME AND LOCALITY OF FIRM OR COMPANY												
SMOKER					HOSPITAL OR TUMOR REGISTRY REPORTING				Name								
					Address				KIND OF BUSINESS OR INDUSTRY								
					ATTENDING PHYSICIAN				USUAL OCCUPATION (DO NOT ENTER RETIRED)								
DATE OF DEATH	Month	Day	Year	NEW YORK STATE DEPARTMENT OF HEALTH				Check here if you wish more space used									
				See Reverse Side for Instructions													

(b) Control Group Selection - Two overlapping control groups will be used, each having a control to case ratio of 1:1. The first group of controls will be selected from drivers license files matched on 5-year age group and zip code (see appendix). The method is based on that developed by P.C. Nasca and J.O. Moore. Alternate controls also will be selected and stratification during analysis shall include race. The sarcoma case group will be matched against drivers license files to see the extent to which the case group have drivers license. This will provide an indication of how representative the control sampling frame is of the case group. As most of the case group would have been expected to live had they not developed sarcoma, this live control group is considered most representative of the general population and thus the appropriate control group for this study.

In order to take into account the possibility that informants for dead cases may not be able to provide equivalent information to that for live controls, a dead control group will also be selected for dead cases. Controls found to be ineligible for military service because of a condition which lead to their subsequent selection as a control will be excluded. Together with the matched controls for the live cases, these will provide a second

control group for analysis. For each dead case two death certificates will be selected for men of the same 5-year age group, years of education, race and health systems area. Health systems areas contain about 10 counties each. Persons dying from all causes except cancer will be eligible to serve as a control.

Positive Control - In addition to the "negative controls" noted above, we will attempt to obtain an age-matched group of "positive controls" -- that is, men known to have served in Vietnam. These controls will be selected only for sarcoma cases with a Vietnam service history. Information on dates of service, battalion company, etc. for these two groups will be collected and compared.

- (c) Tumor Comparisons - Pathology slides will be borrowed from hospital pathologists for review by Dr. Doris Collins of the Division of Labs and Research. Dr. Collins will use a standardized classification form, and be blinded as to the military service experience of the case under study. The distribution of histologic patterns of Vietnam veterans then will be compared to non-Vietnam veterans and non-veterans.

Hospital records will be abstracted for anatomic site of the tumor, diagnostic procedures, and historical information. Again, Vietnam veterans will be compared to non-

Vietnam veterans and non-veterans. (It should be noted that this section relates only to comparisons with the case group rather than case-control comparisons.)

- (d) Interview - Cases and controls, or a close relative or friend if the study subject has died, will be interviewed using a standardized questionnaire. The interview will be done by trained interviewers who have pilot tested the questionnaires. A 10 percent callback will be done by a different interviewer to check on reliability. The survey will be conducted by telephone, or if the study subject prefers, in person. Data will be collected about conditions known or suspected of being associated with soft-tissue sarcoma or which might relate to the possibility of exposure. Thus, in addition to military service history, we will gather data on smoking, alcoholism, occupation, other activities that might be associated with exposure to toxic chemicals, and on questions which relate to the various hypotheses discussed in the background section.

Validation of interview responses relating to military service and further information will be collected by checking against Veterans Administration records. This

procedure will be kept blinded as to case or control status insofar as possible.

- (e) Analysis - Results will be analyzed using traditional epidemiological and biostatistical methods, including current multivariate statistical techniques. This will include the linear logistic model for matched analysis as described by Holford et al (1978) and Breslow et al (1978). The logistic model allows for the direct consideration of continuous risk variables and for multivariate analysis. Further when a single univariate binary risk factor is considered, this model reduces to the method of Miettinen (1974). Statistical power will be shown through the use of confidence limits or other methods.

Associations between selected diseases and putative exposures may arise through a number of biases which affect the collection and interpretation of data from epidemiological studies. The following attention will be given to these potential biases:

- (1) Associations may be based on systematic bias due to non-response. We will attempt to reduce non-response to minimum. Past experience of the Division of Epidemiology shows that we can anticipate a response rate of better than 80%

in both the case and control groups in interview studies. We also plan to compare respondents and non-respondents among both cases and controls according to the variables which are present in the record systems used for case and control ascertainment.

- (2) Bias might be the result of preferential recall on the part of case or control subjects. To minimize this potential bias wherever possible we will use established records to identify or validate military service experience. We also will compare the absolute frequency of military service experience in our study to the data reported from other similar investigations.
- (3) Bias may occur as a result of a systematic differences between cases and controls in terms of access to medical care. We do not expect this to be a major problem for patients with the conditions under study. However, we will collect information about diagnostic procedures and analyze for this possibility.
- (4) An artifactual association or absence of association could occur if eligibility for military service varied between cases and controls. To avoid this, controls found to be ineligible for

military service because of a condition which lead to their death and subsequent selection as a control will be excluded. We do not know if other causes of death; for example, motor vehicle accidents, are more or less likely to occur among veterans. We feel the best way of handling this type of possibility is to select the controls broadly from all disease categories except those under study.

- (5) Confounding by other variables is one of the most frequent sources of bias. We will attempt to minimize this possibility through matching, subject restriction, and multivariate analysis. Attention will be paid to the distinction between variables which are true confounders and those which are part of a causal network. NOTE THAT A MAJOR LIMITATION OF THIS STUDY MAY BE AN INABILITY TO MAKE A DEFINITE STATEMENT ABOUT DIOXIN EXPOSURE EVEN IF CASES TURN OUT TO HAVE MORE MILITARY EXPERIENCE THAN CONTROLS.

I. Part II Study - Part II Study will be an analysis of occupation and industry as reported on death certificates. Study subjects will be all male residents of New York State exclusive of New York City listed on death certificates as dying of soft-tissue sarcomas during the period January 1, 1970 through December 31, 1979. Controls will be selected

from death certificate files matched on date of birth, years of education, race and health systems area. Occupation and industry from the certificates will be analyzed in order to see if any particular occupations or industries are over-represented in the case group. This is considered a hypothesis generating study that may yield a lead for further investigation.

III. Human Subjects - Risks, if any, from epidemiologic studies of this type are minimal. The use of telephone interviews to collect epidemiologic data seems reasonable in light of the number of interviews to be completed. This method does, of course, preclude the procurement of personally signed participant informed consent forms. A substitute method has been developed to serve this purpose. Prior to the interview we will read a standardized text which explains the purposes of the research and the rights of participants. This method has been reviewed and approved by the Human Subjects Committee of the New York State Department of Health under the Federal rules and regulations governing the protection of human subjects (Subtitle A of Title 45, Section 46.10(c)). Signed informed consent will be obtained in the event of a personal interview or medical procedure. Individual records will be kept confidential. Division of Epidemiology employees are trained in confidentiality procedures and the offices protected by security measures which help to assure this confidentiality.

REFERENCES

- Breslow NE, Day NE, Halborg KT, et al. Estimation of multiple relative risk functions in matched case-control studies. *Am J Epidemiol.* 1978; 108:299-307.
- Goldenberg, GJ, Spurr GM, Hogg GR. Simultaneous occurrence of sarcomas in a husband and wife. *Can Med Assoc J.* 1974; 110:49-50.
- Greenberg G. Sarcoma after intramuscular iron injection. *Br Med J.* 1976; 1:1508-09.
- Greenberg G. Sarcoma after intramuscular iron injection. *Br Med J.* 1976; 2:233-34.
- Hanes B, Gardner MB, Loosli CG, Heidbreder G, Kogan B, Marylander H, Huebner RJ. Pet association with selected human cancers: a household questionnaire survey. *J Natl Cancer Inst.* 1970; 45:1155-62.
- Hardell L, Sandstrom A. Case-control study: soft-tissue sarcomas and exposure to phenoxyacetic acids or chlorophenols. *Br J Cancer.* 1979; 39:711-17.
- Hatfield PM, Schulz MD. Postirradiation sarcoma. *Radiology.* 1970; 96:593-602.
- Holford T, White C, Kelsey J. Multivariate analysis for matched case-control studies. *Am J Epidemiol.* 1978; 107:245-256.
- Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms - A familial syndrome? *Ann Intern Med.* 1969; 71:747-52.
- Li FP, Fraumeni JF. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. *J Natl Cancer Inst.* 1969; 43:1365-73.
- Li FP, Fraumeni JF. Familial breast cancer, soft-tissue sarcomas, and other neoplasms. *Ann Intern Med.* 1975; 83:833-34.
- Mierau GW, Favara BE. Rhabdomyosarcoma in children: ultrastructural study of 31 cases. *Cancer.* 1980; 46:2035-40.
- Miettinen OS. Confounding and effect-modification. *Am J Epidemiol.* 1974; 100:350-353.
- Morman MR, Lin RY, Petrozzi JW. Dermatofibrosarcoma protuberans arising in a site of multiple immunizations. *Arch Dermatol.* 1979; 115:1453.
- Morton DL. Soft tissue sarcomas. In: Holland JF, Frei E, ed. *Cancer medicine.* Philadelphia: Lea, Febiger, 1974:1845-61.

Morton DL, Malmgren RA, Hall WT, Schidlovsky G. Immunologic and virus studies with human sarcomas. *Surgery.* 1969; 66:152-61.

Relevance of animal tumours to man. *Lancet.* 1969; 2:418-19.

Safai B, Mike V, Giraldo G, Beth E, Good RA. Association of Kaposi's sarcoma with second primary malignancies - possible etiopathogenic implications. *Cancer.* 1980; 45:1472-79.

Sloane JA, Hubbell MM. Soft tissue sarcomas in children associated with congenital anomalies. *Cancer.* 1969; 23:175-82.

Sobin LH. Sarcomas in Afghanistan. *Nature.* 1968; 217:1072-73.

Stout AP. Sarcomas of the soft tissues. *Ca.* 1961; 11:210-31.

Male Soft Tissue Sarcoma Study Live Control Selection Procedures

Request a selected 5-year age group distribution of male licensed drivers by selected zip code areas of New York State, excluding New York City from the New York State Department of Motor Vehicles. Using these data, determine what percentage of those files must be sampled and put on tape in order to generate the appropriate number of controls. Ask the New York State Department of Motor Vehicles to sample licensed drivers using the following procedures:

1. Select all male licensed drivers between the ages of twenty-five and forty-nine inclusive who reside in selected zip code areas.
2. Stratify each 5-year age group by zip code and using a random starting number between 1 and _____ (to be based on predetermined percentage), choose every _____th driver in each zip code area until the appropriate number of controls has been selected.
3. Create a tape file consisting of the individuals selected in the systematic sample.

Our programmer will then prepare a program which will allow us to print out the information on the tape in a form enabling us to select the controls by random number order. One primary control and five alternate controls will be chosen for each case. They will be matched with the case by sex, year of birth or if necessary, year of birth within a 5-year age group, and zip code at the time of diagnosis. This will be done for each case in the following manner:

1. From a case list including year of birth and zip code at time of diagnosis find year of birth and zip code for the case.
2. Locate the same zip code on the Motor Vehicle printout and the year of birth that matches that of the case.
3. Using the random number generator on the calculator, choose the first six controls that can be used.
4. Fill in a control selection form in duplicate.

12/11/80

STATE OF NEW YORK

S. 9722—A

A. 11729—A

SENATE—ASSEMBLY

May 6, 1980

IN SENATE—Introduced by Sens. COOK, LOMBARDI, BABBUSH, BARTOSIEWICZ, BERMAN, CONNOR, DUNNE, FLYNN, LACK, LAVALLE, LEVY, PISANI, TAURIELLO, VOLKER—read twice and ordered printed, and when printed to be committed to the Committee on Health—reported favorably from said committee and committed to the Committee on Finance—committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

IN ASSEMBLY—Introduced by COMMITTEE ON RULES—(at request of M. of A. Tallon, Behan, Robach, Connors, Grannis, Hinchey, Kidder, Zimmer, Casale, Hannon, McCabe, Schiminger, Larkin, Saland)—read once and referred to the Committee on Health—reported and referred to the Committee on Ways and Means—committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT creating a temporary state commission on dioxin exposure and to amend the public health law, in relation to health effects of exposure to herbicides containing dioxin and making an appropriation therefor

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

- 1 Section 1. A temporary state commission on dioxin exposure is hereby
- 2 created to obtain information relating to the health effects of exposure
- 3 to herbicides containing dioxin for residents of the state of New York,
- 4 including those Vietnam era veterans who may have been exposed to these
- 5 substances during their period of military service. The commission shall
- 6 direct its attention to at least the following:
- 7 (a) Determining what medical, administrative and social assistance is
- 8 needed for victims of dioxin exposure and submit its recommendations to
- 9 the legislature for its consideration;
- 10 (b) Conducting an extensive outreach program to inform Vietnam era
- 11 veterans who may have been exposed to herbicides containing dioxin of
- 12 any federal or state assistance available to them; and

EXPLANATION—Matter in *italics* (underscored) is new; matter in brackets [] is old law to be omitted.

LBD02120508A

1 (c) Acting as the official agent of the state for disseminating in-
2 formation to Vietnam era veterans about epidemiological or other studies
3 relating to dioxin exposure which are being conducted by the federal or
4 state governments.

5 § 2. The commission shall consist of nine members; each to serve for a
6 term of two years, to be appointed by the governor. Five members shall
7 be honorably discharged Vietnam era veterans, with at least one from
8 each judicial department; one shall be a representative of a public em-
9 ployees union; one shall be a representative of a private employees
10 union; one shall be a representative of the business community; and, one
11 member shall be the state health commissioner, or his representative.
12 The commission shall elect a chairman from among its members. Vacancies
13 in the membership of the commission and its officers shall be filled in
14 the manner provided for original appointments. The commission shall meet
15 on the call of the chairman at least four times per year. However, the
16 commissioner of health shall call the initial meeting of the commission
17 not later than December first, nineteen hundred eighty.

18 § 3. The commission may employ and at pleasure remove such personnel
19 as it may deem necessary, including an executive director, for the per-
20 formance of its functions and fix their compensation within the amounts
21 made available therefor.

22 § 4. The members of the commission shall receive no compensation for
23 their services but shall be allowed their actual and necessary expenses
24 incurred in the performance of their duties hereunder.

25 § 5. To the maximum extent feasible, the commission shall be entitled
26 to request and receive and shall utilize and be provided with such
27 facilities, resources and data of any court, department, division,
28 board, bureau, commission or agency of the state or any political sub-
29 division thereof as it may reasonably request to carry out properly its
30 powers and duties hereunder. The commission shall not disclose informa-
31 tion received pursuant to this act so as to divulge the identities of
32 the persons to whom it relates except as is necessary to carry out the
33 purposes of this act.

34 § 6. The commission shall make a preliminary report to the governor
35 and the legislature of its findings, conclusions, and recommendations
36 not later than March first, nineteen hundred eighty-one, and a final
37 report of its findings, conclusions and recommendations not later than
38 March first, nineteen hundred eighty-two.

39 § 7. The public health law is amended by adding a new article twenty-
40 four-B to read as follows:

41 ARTICLE 24-B

42 INFORMATION PROGRAM ON DIOXIN

43 Section 2475. Special policies with respect to dioxin exposure.

44 § 2475. Special policies with respect to dioxin exposure. 1. For
45 the purpose of identifying persons who were exposed to an herbicide con-
46 taining dioxin and for the purpose of compiling data on the health ef-
47 fects of this exposure, the commissioner of health shall:

48 (a) establish, promote and maintain a public information program on
49 dioxin. Such program shall include, but may not be limited to, an ef-
50 fort to contact Vietnam era veterans and employees of the public and
51 private sectors within the state who were exposed to an herbicide con-
52 taining dioxin;

53 (b) initiate an epidemiological study of the health effects of expo-
54 sure to herbicides containing dioxin;

1 (c) maintain a central data bank within the department for informa-
2 tion collected on the health effects of exposure to dioxin and for the
3 cataloguing of existing scientific and medical literature on the health
4 effects of this exposure; and,

5 (d) initiate education for health professionals to assist them in un-
6 derstanding the potential risks and state-of-the-art knowledge with
7 regard to detection, diagnosis and treatment of acute and chronic symp-
8 toms associated with dioxin exposure.

9 2. The commissioner may request and shall receive from any depart-
10 ment, division, board, bureau, commission or agency of the state or of
11 any political subdivision thereof such assistance and data as will ena-
12 ble him to properly carry out his activities hereunder and effectuate
13 the purposes herein set forth. The commissioner may also enter into
14 any contract for services as he deems necessary with a private agency or
15 concern upon said terms and conditions as he deems appropriate. Informa-
16 tion concerning patient and medical data provided to the commissioner
17 pursuant to this subdivision shall be kept confidential according to the
18 provisions of paragraph (i) of subdivision one of section two hundred
19 six of this chapter.

20 3. The commissioner shall make an annual report to the legislature of
21 his findings and recommendations concerning the effectiveness, impact
22 and benefits derived from the special policies as provided for in this
23 section. Such report shall be delivered on or before the first day of
24 March and shall contain evaluations of the policies and any legislation
25 deemed necessary and proper.

26 § 8. The sum of two hundred twenty-five thousand dollars (\$225,000),
27 or so much thereof as may be necessary, is hereby appropriated out of
28 any moneys in the state treasury in the general fund to the credit of
29 the state purposes fund not otherwise appropriated. Of such amount, the
30 sum of seventy-five thousand dollars (\$75,000), is appropriated and made
31 available to the temporary state commission on dioxin exposure and the
32 sum of one hundred fifty thousand dollars (\$150,000), is appropriated
33 and made available to the department of health, to carry out the pur-
34 poses of this act. Such moneys shall be payable on the audit and war-
35 rarrant of the comptroller on vouchers certified or approved in the manner
36 prescribed by law.

37 § 9. This act shall take effect on the first day of September,
38 nineteen hundred eighty.

APPENDIX

NEW YORK STATE DEPARTMENT OF HEALTH CERTIFICATE OF DEATH

CENSUS TRACT SUB-DIVISION

RECORDED DISTRICT REGISTER NUMBER

STATISTICAL DISTRICT EC ES

1 NAME FIRST MIDDLE LAST 2 SEX MALE FEMALE 3A DATE OF DEATH 3B HCU

4 AGE IF UNDER 1 YEAR IF UNDER 1 DAY 5 DECEDENT BORN 6 VETERAN OF U.S. ARMED FORCES 7 SOCIAL SECURITY NUMBER

8A COUNTY OF DEATH 8B LOCALITY (CHECK ONE AND SPECIFY) 8C HOSPITAL OR OTHER INSTITUTION 8D IF IN HOSPITAL OR INSTITUTION 8E IF INPATIENT ADMISSION D.

9 STATE OF BIRTH 10 CITIZEN OF WHAT COUNTRY 11 MARITAL STATUS 12 SURVIVING SPOUSE

13 RACE 14 OF SPANISH ORIGIN 15 EDUCATION

16A USUAL OCCUPATION 16B KIND OF BUSINESS OR INDUSTRY 16C NAME AND LOCALITY OF FIRM OR COMPANY

17A STATE 17B COUNTY 17C LOCALITY 17E IF CITY OR VILLAGE IS RESIDENCE WITHIN CITY OR VILLAGE LIMITS

17D STREET AND NUMBER OF RESIDENCE (INCLUDE ZIP CODE)

18A NAME OF FATHER 18B MAIDEN NAME OF MOTHER

19A NAME OF INFORMANT 19B MAILING ADDRESS

20A BURIAL, CREMATION, REMOVAL OR OTHER DISPOSITION 20B PLACE OF BURIAL, CREMATION, REMOVAL OR OTHER DISPOSITION 20C LOCATION

21A NAME AND ADDRESS OF FUNERAL HOME 21B REGISTRATION NO.

22A NAME OF FUNERAL DIRECTOR 22B SIGNATURE OF FUNERAL DIRECTOR 22C REGISTRATION NO.

23A SIGNATURE OF REGISTRAR 23B DATE FILED 24A BURIAL OR REMOVAL PERMIT ISSUED 24B MONTH DAY YEAR

TO BE COMPLETED BY CERTIFYING PHYSICIAN ONLY -OR- TO BE COMPLETED BY CORONER OR MEDICAL EXAMINER ONLY

25. A. TO THE BEST OF MY KNOWLEDGE, DEATH OCCURRED AT THE TIME, DATE AND PLACE AND DUE TO THE CAUSES STATED

SIGNATURE MONTH DAY YEAR

B. THE PHYSICIAN ATTENDED THE DECEASED C. LAST SEEN ALIVE

D. NAME OF ATTENDING PHYSICIAN, IF OTHER THAN CERTIFIER

26 NAME AND ADDRESS OF CERTIFIER

27. DEATH WAS CAUSED BY ENTER ONLY ONE CAUSE PER LINE FOR (A), (B) AND (C).

PART I IMMEDIATE CAUSE (A) DUE TO OR AS A CONSEQUENCE OF.

(B) DUE TO OR AS A CONSEQUENCE OF. (C) OTHER SIGNIFICANT CONDITIONS

28A AUTOPSY 28B IF YES WERE FINDINGS CONSIDERED IN DETERMINING THE CAUSE OF DEATH? 29 WAS CASE REFERRED TO CORONER OR MEDICAL EXAMINER

30A SPECIFY IF ACCIDENT, HOMICIDE, SUICIDE, UNDETERMINED, PENDING INVESTIGATION 30B DATE OF INJURY 30C HOUR OF INJURY 30D DESCRIBE HOW INJURY OCCURRED

30E INJURY AT WORK? 30F PLACE OF INJURY HOME, FACTORY, OFFICE BLDG., ETC 30G LOCATION (STREET & NO., CITY OR VILLAGE, TOWN, COUNTY, STATE)

USUAL RESIDENCE WHERE DECEDENT LIVED.

CONDITIONS IF ANY WHICH GAVE RISE TO IMMEDIATE CAUSE OR AS STATING THE UNDERLYING CAUSE LAST

HS